ArticleNature2025
Perturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiation.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Transposable Element Activation: A Hallmark of Cancer.Cancer discovery · 2026Review
- APN Inhibitor Bestatin Induces MM Cell Differentiation Through the CD79B/BTK/STAT3 Pathway.Cells · 2026Article
- Targeting ZMIZ1 induces differentiation in acute myeloid leukemia via chromatin remodeling.Signal transduction and targeted therapy · 2026Article
- mNature communications · 2026Article
- Cytoplasmic retention of IRF3 binding Vimentin competitively with ERK1/2 mitigates acute myeloid leukemia through TFEB nuclear translocation.Cell communication and signaling : CCS · 2026Article
- FOXJ3 drives mesenchymal stem cell osteogenic differentiation via the Wnt/β‑catenin pathway: A novel regulator implicated in osteoporosis.Molecular medicine reports · 2026Article
- The role of epigenetic modifications in hematological cancers.Frontiers in oncology · 2026Review
- Cancer Reversion Therapy: Prospects, Progress and Future Directions.Current issues in molecular biology · 2025Review
- Review
- Combinatorial inhibition of LSD1 and Menin induces therapeutic differentiation in AML.bioRxiv : the preprint server for biology · 2025Article
- Drug Repurposing for AML: Structure-Based Virtual Screening and Molecular Simulations of FDA-Approved Compounds with Polypharmacological Potential.Biomedicines · 2025Article
- Co-targeting menin and LSD1 dismantles oncogenic programs and restores differentiation in MLL-rearranged AML.bioRxiv : the preprint server for biology · 2025Article
- Combined inhibition of lysine-specific demethylase 1 and kinase signaling as a preclinical treatment strategy in glioblastoma.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Amir Hosseini *Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0001-8229-832X
Abhinav Dhall *Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Nemo IkonenInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland.ORCID 0000-0003-4022-4394
Natalia SikoraLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0001-6457-6365
Sylvain NguyenLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0002-6508-1337
Yuqi ShenMedical Research Council Weatherall Institute of Molecular Medicine (MRC WIMM), University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK.ORCID 0009-0008-9114-8743
Maria Luisa Jurgensen AmaralCell and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.
Alan JiaoLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Felice WallnerLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Philipp SergeevInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-0234-1568
Yuhua LimLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID 0009-0008-3084-3654
Yuanqin YangLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Binje VickResearch Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Munich, German Research Center for Environmental Health, Munich, Germany.ORCID 0000-0003-1956-2778
Kimihito Cojin KawabataDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA.
Ari MelnickDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-8074-2287
Paresh VyasMedical Research Council Weatherall Institute of Molecular Medicine (MRC WIMM), University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK.ORCID 0000-0003-3931-0914
Bing RenCell and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0002-5435-1127
Irmela JeremiasResearch Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Munich, German Research Center for Environmental Health, Munich, Germany.
Bethan PsailaLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0001-8198-9663
Caroline A HeckmanInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland. caroline.heckman@helsinki.fi.ORCID 0000-0002-4324-8706
M Andrés BlancoDepartment of Biomedical Sciences, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA. ablanco@vet.upenn.edu.ORCID 0000-0003-4404-2301
Yang ShiLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK. yang.shi@ludwig.ox.ac.uk.ORCID 0000-0001-9713-1709
Funding
Investigating the role of KAT6A in MLL-rearranged acute myeloid leukemiaR01CA266641 · NCI · UNIVERSITY OF PENNSYLVANIA · 2022 to 2025
$1.2MNCI NIH HHS R01 CA266641NCI NIH HHS R35 CA210104
Abstract
Impaired differentiation is a hallmark of myeloid malignancies
Indexed as
Cell DifferentiationHistone DemethylasesLeukemia, Myeloid, AcuteTranscription, GeneticWnt Signaling PathwayAnimalsbeta CateninCell Line, TumorFemaleGlycogen Synthase Kinase 3HumansMaleMiceSTAT1 Transcription FactorXenograft Model Antitumor Assaysbeta CateninGlycogen Synthase Kinase 3Histone DemethylasesKDM1A protein, humanSTAT1 protein, humanSTAT1 Transcription Factor
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.